Definium Therapeutics Q2 net loss $159M; Phase 3 Emerge MDD study meets primary endpoint

Definium Therapeutics, Inc.

Phase 3 Emerge in MDD met primary endpoint: 8.1-point MADRS improvement vs placebo at Week 6 (p<0.0001).
Cash, equivalents and investments $1.1B as of June 30, 2026, up from $411.6M at Dec 31, 2025.
Net loss $159.0M for Q2 2026 vs $42.7M in Q2 2025, including $86.2M non-cash warrant liability charge.
R&D expenses $48.7M, G&A $26.4M; completed public offering of $805M gross proceeds.
Topline GAD results from Voyage expected week of Aug 10; Panorama in Sept 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.